Temperature excursion: difference between revisions
Diff·revision 8 → 9·19:26, 15 Jun 2025
Difference between revision 8 and revision 9 of Temperature excursion. 3 lines changed; the page grew by 652 bytes.
| Revision 8 — 01:32, 6 Jun 2025 Chromatokid (talk) add category for logistics 9,465 bytes +180 | Revision 9 — 19:26, 15 Jun 2025 Chromatokid (talk) add the cross-link to the temperature-excursion article 10,117 bytes +652 | ||
|---|---|---|---|
| 51 | Allowances are as stated in the respective prescribing information and differ between jurisdictions; the figures above follow United States labelling and are cited to the labels rather than to secondary summaries.{{r|pi_ozempic,pi_wegovy,pi_mounjaro,pi_trulicity,pi_victoza}} | 51 | Allowances are as stated in the respective prescribing information and differ between jurisdictions; the figures above follow United States labelling and are cited to the labels rather than to secondary summaries.{{r|pi_ozempic,pi_wegovy,pi_mounjaro,pi_trulicity,pi_victoza}} |
| 52 | 52 | ||
| + | 53 | Three features of this table matter for interpretation. The allowances are single, non-renewable periods, not a budget that resets: a pen that has spent 21 days at room temperature has consumed the allowance whether or not it is subsequently refrigerated. They differ substantially between products with similar chemistry, which reflects differences in formulation, container and the stability data generated rather than differences in the peptide. And they are stated as maxima at a ceiling temperature, so a period at 35 °C is outside the allowance entirely rather than being a shorter permitted period.{{r|ich_q1a}} | |
| + | 54 | ||
| 53 | == References == | 55 | == References == |
| 54 | {{reflist}} | 56 | {{reflist}} |
| ⋮ | ⋮ | ||
| 73 | [[Category:Peptide degradation]] | 75 | [[Category:Peptide degradation]] |
| 74 | [[Category:Logistics]] | 76 | [[Category:Logistics]] |
| + | 77 | [[Category:Clinical practice]] | |
| 75 | 78 |